• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    5/30/23 1:31:24 PM ET
    $ACON
    $AVAH
    $CMRA
    $EFTR
    Medical Specialities
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Aclarion (NASDAQ:ACON) stock moved upwards by 71.2% to $1.01 during Tuesday's regular session. As of 13:30 EST, this security is trading at a volume of 38.3 million shares, making up 2971.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.9 million.
    • T2 Biosystems (NASDAQ:TTOO) shares increased by 65.96% to $0.16. Trading volume for this security as of 13:30 EST is 215.2 million, which is 12309.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million.
    • GreenLight Biosciences (NASDAQ:GRNA) shares increased by 45.41% to $0.29. Trading volume for this security as of 13:30 EST is 6.7 million, which is 1652.1% of its average full-day volume over the last 100 days. The company's market cap stands at $44.0 million.
    • Monopar Therapeutics (NASDAQ:MNPR) stock rose 29.74% to $1.19. Trading volume for Monopar Therapeutics's stock is 6.7 million as of 13:30 EST. This is 22515.2% of its average full-day volume over the last 100 days. The company's market cap stands at $15.7 million.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) stock increased by 26.21% to $0.83. The current volume of 9.0 million shares is 1179.7% of eFFECTOR Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $35.3 million.
    • Aveanna Healthcare Hldgs (NASDAQ:AVAH) shares increased by 26.15% to $1.23. The current volume of 478.5K shares is 104.2% of Aveanna Healthcare Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $228.6 million.

    Losers

    • TScan Therapeutics (NASDAQ:TCRX) stock fell 23.8% to $2.43 during Tuesday's regular session. As of 13:30 EST, TScan Therapeutics's stock is trading at a volume of 438.5K, which is 31.8% of its average full-day volume over the last 100 days. The company's market cap stands at $58.8 million.
    • 9 Meters Biopharma (NASDAQ:NMTR) stock decreased by 21.24% to $0.63. As of 13:30 EST, 9 Meters Biopharma's stock is trading at a volume of 292.0K, which is 366.7% of its average full-day volume over the last 100 days. The company's market cap stands at $9.1 million.
    • Oncorus (NASDAQ:ONCR) shares fell 17.98% to $0.18. Trading volume for Oncorus's stock is 860.7K as of 13:30 EST. This is 417.6% of its average full-day volume over the last 100 days. The company's market cap stands at $4.7 million.
    • Comera Life Sciences (NASDAQ:CMRA) stock fell 15.23% to $0.48. The market value of their outstanding shares is at $10.7 million.
    • MyMD Pharmaceuticals (NASDAQ:MYMD) shares fell 15.09% to $1.84. As of 13:30 EST, this security is trading at a volume of 581.5K shares, making up 108.0% of its average full-day volume over the last 100 days. The company's market cap stands at $72.9 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares decreased by 15.05% to $3.67. As of 13:30 EST, this security is trading at a volume of 428.4K shares, making up 12.6% of its average full-day volume over the last 100 days. The company's market cap stands at $7.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AVAH
    $CMRA
    $EFTR

    CompanyDatePrice TargetRatingAnalyst
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    TScan Therapeutics Inc.
    $TCRX
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Aveanna Healthcare Holdings Inc.
    $AVAH
    11/13/2025$11.00Outperform
    BMO Capital Markets
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    Monopar Therapeutics Inc.
    $MNPR
    10/13/2025$125.00Overweight
    Barclays
    Aveanna Healthcare Holdings Inc.
    $AVAH
    9/18/2025$10.00Underweight → Neutral
    Analyst
    More analyst ratings

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CCSO Rodriguez Susan

    4 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:43 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rodriguez Susan

    3 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Shaner Jeff sold $3,411,399 worth of shares (461,909 units at $7.39), decreasing direct ownership by 15% to 2,650,892 units (SEC Form 4)

    4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    2/19/26 9:16:05 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Aveanna

    William Blair initiated coverage of Aveanna with a rating of Outperform

    12/8/25 8:33:04 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    TScan Therapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded TScan Therapeutics from Overweight to Equal-Weight

    11/14/25 10:24:29 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACON
    $AVAH
    $CMRA
    $EFTR
    SEC Filings

    View All

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Aveanna Healthcare Holdings Announces Agreement to Acquire Family First Homecare

    ATLANTA, March 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it has entered into an agreement to acquire Family First Holding, LLC ("Family First Homecare"). Family First Homecare is a scaled, multi-state provider of pediatric home care that primarily provides skilled Private Duty Nursing services with 27 locations in seven states including Florida, Illinois, Iowa, Pennsylvania, South Dakota, Texas, and North Carolina, where it is currently launching operations. The acquisition of Family First Homecare expands Aveanna'

    3/12/26 7:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aclarion CEO Brent Ness to Attend LSI USA 2026

    BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders. During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion's continued progress advancing NOCISCAN, the company's proprietary MR spectroscopy pl

    3/12/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (

    3/4/26 7:00:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    3/12/26 7:30:26 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    SEC Form S-8 filed by TScan Therapeutics Inc.

    S-8 - TScan Therapeutics, Inc. (0001783328) (Filer)

    3/4/26 7:42:13 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by TScan Therapeutics Inc.

    10-K - TScan Therapeutics, Inc. (0001783328) (Filer)

    3/4/26 7:30:55 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lynx1 Capital Management Lp bought $73,552 worth of shares (81,732 units at $0.90) and bought $71,974 worth of shares (80,069 units at $0.90) (SEC Form 4)

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    12/23/25 6:17:28 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Financials

    Live finance-specific insights

    View All

    Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March

    2/26/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook

    Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year periodThird Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year periodAdjusted EBITDA for Q3 2025 was $80.1 million, a 67.5% increase over the prior year periodIncreased Full Year 2025 Revenue guidance to greater than $2.375 billion, updated from greater than $2.3 billion Increased Full Year 2025 Adjusted EBITDA guidance to greater than $300 million, updated from greater than $270 million ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, hi

    11/6/25 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

    Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to focus clinical development on heme program and initiate pre-clinical development of in vivo-engineered TCR-T for solid tumors Strategic prioritization extends cash runway into H2 2027 Conference call and webcast scheduled for Monday, November 3, 8:00 a.m. Eastern Time WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology comp

    11/3/25 6:30:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

    SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

    11/14/24 4:40:11 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

    SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

    11/14/24 4:05:31 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AVAH
    $CMRA
    $EFTR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care